Abstract
In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.
Keywords: Immunosuppressive therapy, toxicity, auto-immune neurologic disease, multiple sclerosis (MS), peptic disease, CNS vasculitides, Cyclophosphamide therapy, myasthenia gravis (MG), proximal myopathy
Current Neuropharmacology
Title: Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Volume: 9 Issue: 3
Author(s): Enrico C. Lallana and Camilo E. Fadul
Affiliation:
Keywords: Immunosuppressive therapy, toxicity, auto-immune neurologic disease, multiple sclerosis (MS), peptic disease, CNS vasculitides, Cyclophosphamide therapy, myasthenia gravis (MG), proximal myopathy
Abstract: In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.
Export Options
About this article
Cite this article as:
C. Lallana Enrico and E. Fadul Camilo, Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases, Current Neuropharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157015911796557939
DOI https://dx.doi.org/10.2174/157015911796557939 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Chemokines in Cardiac Repair
Current Pharmaceutical Design Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology A Mitochondrial Approach to Cardiovascular Risk and Disease
Current Pharmaceutical Design Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Dapagliflozin Protects H9c2 Cells Against Injury Induced by Lipopolysaccharide via Suppression of CX3CL1/CX3CR1 Axis and NF-κB Activity
Current Molecular Pharmacology AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Clinical Applications for Cardiovascular Magnetic Resonance Imaging at 3 Tesla
Current Cardiology Reviews Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Targeting the Cardiomyocyte Cell Cycle for Heart Regeneration
Current Drug Targets MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Blockade of Renin Angiotensin System Ameliorates the Cardiac Arrhythmias and Sympathetic Neural Remodeling in Hearts of Type 2 DM Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Secondary Prevention of Ischemic Stroke
Current Drug Targets Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Update on the Evaluation and Management of Brief Resolved Unexplained Events (Previously Apparent Life-Threatening Events)
Reviews on Recent Clinical Trials Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry